HEMATOLOGY

Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.

A triplet regimen consisting of chlorambucil and rituximab in combination with an individualized dose of lenalidomide can potentially be used as a frontline treatment for patients with advanced chronic lymphocytic leukemia who are older or unfit for standard treatment with fludarabine, cyclophosphamide, and rituximab.

The FDA-approved CAR T-cell therapies have instituted a new era of effective cancer therapies for patients and are the most expensive treatments to date. Now, physicians are faced with financial implications before introducing these novel agents into clinical practice.

Chronic Lymphocytic Leukemia

Stephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

Eli Lilly and Company will acquire Loxo Oncology for an estimated $8 billion in cash, the company has announced.

Relapsed Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, discusses phase II findings with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in CLL.

In a merger agreement announced today, Bristol-Myers Squibb will be acquiring Celgene Corporation in a $74 billion deal to be paid with a combination of cash and stocks.

Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients &ge;1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br /> &nbsp;

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;December 2018, including several new approvals, an accelerated approval, and a priority review.

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma